1/13
08:42 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
1/12
08:30 am
oric
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Low
Report
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
1/9
06:10 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
06:05 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/6
04:05 pm
oric
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/8
09:27 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
High
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
12/8
07:22 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
12/5
08:00 pm
oric
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025
12/5
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/5
01:00 am
oric
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
12/4
09:45 pm
oric
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
12/3
04:01 pm
oric
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
Medium
Report
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
12/1
08:52 am
oric
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 [Yahoo! Finance]
Medium
Report
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 [Yahoo! Finance]
12/1
08:00 am
oric
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
Low
Report
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
11/26
04:34 am
oric
How New ORIC-944 Trial Results and Earnings Update Will Impact ORIC Pharmaceuticals (ORIC) Investors [Yahoo! Finance]
Low
Report
How New ORIC-944 Trial Results and Earnings Update Will Impact ORIC Pharmaceuticals (ORIC) Investors [Yahoo! Finance]
11/24
04:05 pm
oric
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
11/23
02:11 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) was downgraded by analysts at
Wall St
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) was downgraded by analysts at
Wall St
11/20
08:07 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
11/18
07:06 pm
oric
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
11/18
11:04 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "overweight" rating on the stock.
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at JPMorgan Chase & Co. from $17.00 to $20.00. They now have an "overweight" rating on the stock.
11/18
09:00 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/17
10:23 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at Citigroup Inc. from $12.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target raised by analysts at Citigroup Inc. from $12.00 to $16.00. They now have a "buy" rating on the stock.
11/14
11:07 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/14
12:15 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/14
10:32 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $19.00. They now have an "overweight" rating on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $19.00. They now have an "overweight" rating on the stock.